Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $4.0 million.

  • Enanta Pharmaceuticals' Non-cash Items rose 1544.69% to $4.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.0 million, marking a year-over-year increase of 1544.69%. This contributed to the annual value of $6.5 million for FY2025, which is 8543.94% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Non-cash Items stood at $4.0 million for Q4 2025, which was up 1544.69% from $6.5 million recorded in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Non-cash Items peaked at $97.2 million during Q4 2021, and registered a low of $459000.0 during Q4 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' median Non-cash Items value was $3.6 million (recorded in 2025), while the average stood at $18.2 million.
  • In the last 5 years, Enanta Pharmaceuticals' Non-cash Items tumbled by 9739.91% in 2023 and then skyrocketed by 65315.9% in 2024.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Non-cash Items stood at $97.2 million in 2021, then plummeted by 81.84% to $17.6 million in 2022, then plummeted by 97.4% to $459000.0 in 2023, then surged by 653.16% to $3.5 million in 2024, then increased by 15.45% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q4 2025, $6.5 million for Q3 2025, and $3.9 million during Q2 2025.